ERCC1、RRM1、TS蛋白表达对晚期非小细胞肺癌个体化治疗的临床观察

doi:10.3969/j.issn.1000-8535.2017.05.015

广州医药 ›› 2017, Vol. 48 ›› Issue (5): 57-60.DOI: 10.3969/j.issn.1000-8535.2017.05.015

ERCC1、RRM1、TS蛋白表达对晚期非小细胞肺癌个体化治疗的临床观察

赵美玲¹, 蔡小华², 杨方方¹, 向琪¹, 曹小飞¹

1 广州市第一人民医院南沙医院肿瘤血液科 (广州 511457)
2 中山大学附属第一医院东院检验科 (广州 510700)

收稿日期:2017-05-22 发布日期:2021-12-01
通讯作者: 曹小飞,E-mail:38438789@qq.com

Clinical observation on individualized treatment of ERCC1、RRM1、TS expression in later period non small cell lung cancer

ZHAO Meiling, CAI Xiaohua, YANG Fangfang, XIANG Qi, CAO Xiaofei

Received:2017-05-22 Published:2021-12-01

摘要/Abstract

摘要： 目的探讨ERCC1、RRM1、TS蛋白表达对晚期非小细胞肺癌(NSCLC)个体化治疗的指导意义。方法收集经病理确诊的晚期NSCLC患者87例,其中67例愿意接受药敏免疫组化检测的患者作为研究组,采用SP法检测肿瘤组织ERCC1、RRM1、TS蛋白表达,并根据蛋白表达情况选择化疗方案;另外20例患者不进行药敏免疫组化检测,以常规吉西他滨联合顺铂方案化疗,以此作为对照组。比较两组患者化疗的有效率,疾病控制率(DCR),并以无进展生存期(PFS)为指标比较患者预后。结果研究组67例患者中,PR 33例(49.25%),SD 13例(19.4%),PD 21例(31.35%);对照组20例患者中,PR 4例(20%),SD 4例(20%),PD 12例(60%),两组疗效之间有差异( χ²=6.437,P=0.04),研究组DCR为68.6%,高于对照组DCR 40%,差异有统计学意义(χ²=5.372,P=0.034)。研究组患者的中位PFS高于对照组,研究组的PFS为5月,对照组为3月,差异有统计学意义(P＜0.05)。结论对晚期NSCLC患者进行ERCC1、RRM1、TS药敏蛋白免疫组化检测,指导个体化治疗方案,能提高患者化疗的疾病控制率及延长患者的疾病进展时间。

关键词: RRM1, ERCC1, TS, 非小细胞肺癌

赵美玲, 蔡小华, 杨方方, 向琪, 曹小飞. ERCC1、RRM1、TS蛋白表达对晚期非小细胞肺癌个体化治疗的临床观察[J]. 广州医药, 2017, 48(5): 57-60.

ZHAO Meiling, CAI Xiaohua, YANG Fangfang, XIANG Qi, CAO Xiaofei. Clinical observation on individualized treatment of ERCC1、RRM1、TS expression in later period non small cell lung cancer[J]. Guangzhou Medical Journal, 2017, 48(5): 57-60.

参考文献

[1] SCHILLER J H, HARRINGTON D, BELANI C P,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J Med, 2002, 346(2): 92-98.
[2] OHE Y, OHASHI Y, KUBOTA K,et al. Randomized phase Ⅲ study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-arm cooperative study in Japan[J]. Ann Oncol, 2007, 18(2):317-323.
[3] LENG X F, CHEN M W, XIAN L, et al. Combined analysis of mRNA expression of ERCC1,BAG-1,BRCA1,RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy[J]. J Exp Clin Cancer Res,2012, 31 (1):25.
[4] BOUKOVINAS I, PAPADAKI C, MENDEZ P, et al. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients[J]. PLoS One, 2008, 3(11):e3695.
[5] ZUCALI P A, GIOVANNETTI E, DESTRO A, et al. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin[J]. Clin Cancer Res,2011,17(8):2581-2590.
[6] OLAUSSEN K A, DUNANT A, FOURET P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy[J]. N Engl J Med, 2006, 355(10):983-991.
[7] LEE J J, MAENG C H, BAEK S K,et al. The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC)[J]. Lung Cancer, 2010, 70(2):205-210.
[8] RIGHI L, PAPOTTI M G, CEPPI P, et al. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy[J]. J Clin Oncol, 2010, 28(9): 1534-1539.
[9] KASSIS E S, VAPORCIYAN A A, SWISHER S G, et al. Application of the revised lung cancer staging system (IASLC staging project) to a cancer center population[J]. J Thorac Cardiovasc Surg, 2009, 138(2):412-418.
[10] 李红梅,李海霞,刘克为,等.含顺铂三种化疗方案治疗非小细胞肺癌的临床研究[J]. 山东大学学报(医学版),2007,45(5):499-502.
[11] 崔同建,刘振华,陈峥,等.晚期非小细胞肺癌4种化疗方案临床对照研究[J]. 肿瘤学杂志,2006,12(2):136-138.
[12] ALTAHA R, LIANG X, YU J J, et al. Excision repair cross complementinggroup1: gene expression and platinum resistance[J]. Int J Mol Med,2004,14(6):959-970.
[13] COBO M, ISLA D, MASSUTI B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing1 mRNA expression: a phase Ⅲ trial in non-small-cell lung caner[J]. J Clin Oncol, 2007, 25(19): 2747-2754.
[14] KIM S O, JEONG J Y, KIM M R,et al: Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene[J]. Clin Cancer Res, 2008, 14(10):3083-3088.
[15] WANG X, WANG Y, WANG Y, et al. Association of thymidylate synthase gene 3′-untranslated region polymorphism with sensitivity of non-small celllung cancer to pemetrexed treatment:TS gene polymorphism and pemetrexed sensitivity in NSCLC[J]. J Biomed Sci,2013(20):5.

ERCC1、RRM1、TS蛋白表达对晚期非小细胞肺癌个体化治疗的临床观察

Clinical observation on individualized treatment of ERCC1、RRM1、TS expression in later period non small cell lung cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 4

编辑推荐

Metrics

本文评价

[1]	谢建将, 陈敏东, 陈曲海, 陈文广, 梁登峰, 徐子迅, 白文杰. 对比单孔、单操作孔及三孔胸腔镜肺叶切除术治疗早期非小细胞肺癌的临床研究[J]. 广州医药, 2017, 48(5): 32-35.
[2]	张英燕, 曾建芳, 罗秀玉. 同步放化疗治疗晚期非小细胞肺癌的疗效观察[J]. 广州医药, 2016, 47(3): 26-27.
[3]	田丹, 汪森明, 程越, 王军. 紫杉醇脂质体与紫杉醇联合顺铂治疗晚期非小细胞肺癌的临床研究[J]. 广州医药, 2016, 47(2): 24-26.
[4]	徐舒, 冯高飞, 宋雨鸿. 参一胶囊维持治疗对晚期NSCLC患者炎症因子影响的回顾性研究[J]. 广州医药, 2016, 47(1): 15-17.